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Abstract
The tumor microenvironment (TME) serves as an innate resistance niche for chemotherapy assault 
and a physiological barrier against therapeutic nanoparticles (NP) penetration. Previous studies 
have indicated that therapeutic NP can distribute to and deplete tumor associated fibroblasts (TAF) 
for improved therapeutic outcome. However, resistance develops after repeated chemotherapeutic 
NP exposure. In this study, we explored NP-delivered cisplatin induced resistance in the TME by 
investigating the effects of NP damaged TAF on neighboring naïve cells and comparing the 
stroma structure of single and multiple dose NP treatments. Our study suggested that although off-
targeted NP damaged TAF initially inhibited tumor growth, chronic exposure of TAF to cisplatin 
NP led to elevated secretion of Wnt16 in a paracrine manner that supported tumor cell resistance 
and stroma reconstruction. Our study demonstrates that knockdown of Wnt16 in the damaged 
TAF could be a promising combinatory strategy to improve efficacy of NP delivered cisplatin in a 
stroma-rich bladder cancer model.
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1. Introduction
Cisplatin-based chemotherapy is considered the gold standard in the treatment of muscle 
invasive bladder cancer (MIBC). Despite the encouraging initial responses to cisplatin 
induced DNA damage, acquired resistance develops gradually after multiple cycles, 
contributing to the ultimate failure of the treatment. Efforts that modulate cisplatin 
sensitivity mainly focused on reversing the tumor cell autonomous resistance mechanism 
through co-delivery with another regimen that inhibits DNA repair enzymes, cisplatin export 
and others.1–4 However, inconsistency between the ex vivo prediction of combinatory drug 
sensitivity and the in vivo therapeutic outcome suggests that stroma cells in the tumor 
microenvironment (TME) also play a key role in cisplatin mediated resistance.5 Stroma cells 
in the TME, including tumor associated macrophages (TAM), tumor associated fibroblasts 
(TAF) and endothelial cells, build a physical barrier by crosslinking with the extracellular 
matrix, modulating pericyte coverage of vascular fenestration and maintaining a high 
interstitial pressure to inhibit therapeutic molecules and NP penetration.6, 7 They can also 
mediate tumor cell-resistance in a paracrine manner by secreting cytokines and growth 
factors.8–13 Yet, the innate resistance from the TME still fails to explain the discrepancy 
between early stage treatment sensitivity and late stage therapeutic failure. This indicates 
that acquired resistance in the stroma cells in response to DNA damage may occur gradually 
during repeated treatments.
Cisplatin selectively binds with DNA by crosslinking the DNA double strands and inducing 
damage.14, 15 Recent research indicates that DNA damage can lead to cell apoptosis and 
senescence.16, 17 The damaged cells not only produce extracellular signals to reinforce the 
senescent arrest and promote apoptosis by autocrine or paracrine mechanisms16, 18, but also 
secrete pro-survival factors to promote the survival and growth of neighboring cells.19–21 
Tumors and benign stroma cells, especially TAF, have been reported to respond differently 
to DNA damage by secreting different factors.9 This plays an important role in acquired 
resistance.9, 22 Wnt16, a member of the WNT family, belongs to the aforementioned 
secretion factors that have been recently reported and is overexpressed in TAF, rather than 
the tumor cells, upon DNA damage.9 Overexpression of Wnt16 in TAF is found in prostate, 
breast and ovarian cancers. Mutation of the Wnt pathway is closely related to 
carcinogenesis, stemness and angiogenesis in various cancers and disease models.23–25 
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Wnt16 plays a potentially significant role in regulating the crosstalk between neighboring 
cells during DNA damage.
Different from small molecules, nanoparticles (NP) have been designed to improve drug 
pharmacokinetics, facilitate their accumulation and reduce off-target adverse effects in the 
treatment of bladder cancer. In previous work we developed a lipid-coated, platinum-filled 
NP system, known as LPC, for the delivery of cisplatin (cisplatin NP).26 This cisplatin NP, 
with cisplatin as both the material and the drug, was characterized with an 80 wt% loading 
efficiency and was approximately 30 nm in diameter (Supplementary Fig. S1).27 
Polyethylene glycol was conjugated onto the surface of NP for prolonged systemic 
circulation.28 Anisamide, a ligand for the sigma receptor, which is overexpressed on the 
surface of cancerous epithelial cells, was coated on the NP to enhance receptor mediated 
endocytosis. Cisplatin NP have been proposed for the treatment of aggressive bladder cancer 
and have shown a significant antitumor effect compared to free cisplatin.29 Although the NP 
was designed to specifically target tumor cells, off-target distribution of NP in the TAF has 
also been reported. 29, 30 Therefore, we hypothesized that the distribution of cisplatin NP to 
TAF could lead to their damage and subsequently elevate secretion of Wnt16. We also 
hypothesize that downregulation of Wnt16 in TAF could inhibit cisplatin NP mediated 
resistance and enhance the therapeutic anti-tumor efficacy.
Several studies have demonstrated functional blocking of Wnt-canonical β-catenin pathway 
using monoclonal antibodies or small molecule inhibitors.31 However, undesired off-target 
effects have led to safety concerns in this approach. RNA interference provides an 
alternative way to maintain specificity while also improving safety. Liposome-protamine-
hyaluronic acid NP (LPH-NP) was used to encapsulate siRNA and was shown to be an 
effective delivery tool in various tumor models.32 Therefore, we propose a combination 
therapy of cisplatin NP and LPH-NP delivered siRNA against Wnt16 (siWnt NP) 
(Supplementary Fig. S1). This is the first time that siRNA against Wnt16 and cisplatin has 
been proposed as a combinatory strategy to improve therapeutic outcome.
In the current study, a stroma rich bladder cancer model (SRBC) was established by co-
inoculating human basal type bladder tumor UMUC3 with mouse NIH 3T3 fibroblasts. This 
model resembles bladder tumor patient samples in the components and in the morphology of 
the TME.29 In the SRBC model, we investigated the off-target effect of cisplatin NP on TAF 
damage, the Wnt16 secretion level and antitumor efficacy. We also studied the role of 
cytokines, such as Wnt16 in the regulation of crosstalk between tumor cells and the TME. 
We conclude that targeting tumor-stroma regulatory cytokines in the TME along with NP-
delivered chemotherapy could potentially overcome intratumoral off-target effects and 
improve treatment responses.
2. Material and Methods
2.1 Materials
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy(polyethyleneglycol)-2000) 
ammonium salt (DSPE-PEG2000), 1,2-dioleoyl-3-trimethylammonium-propane chloride 
salt (DOTAP), dioleoyl phosphatidic acid (DOPA) were obtained from Avanti Polar Lipids 
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(Alabaster, AL). Cholesterol, hyaluronic acid (HA), protamine sulfate (fraction ×from 
salmon), hexanol, triton-100, cyclohexane were obtained from Sigma-Aldrich (St Louis, 
MO). Cisplatin was purchased from Acros Organics (Fair Lawn, NJ). All the other 
chemicals were purchased from Sigma-Aldrich unless otherwise mentioned. DSPE-PEG-AA 
was synthesized based on the previous established protocols 33. The mouse Wnt16 siRNA 
with sequence 5’-CCAACUACUGCGUGGAGAA-3’ and the control siRNA with sequence 
5’-AATCTCCGAACGTGTCACGT-3’ were purchased from Sigma-Aldrich.
The human bladder transitional cell line (UMUC3) was provided by Dr. William Kim and 
the mouse embryonic fibroblast cell line (NIH 3T3) was purchased from UNC Tissue 
Culture Facility. These two cell lines were maintained in Dulbecco’s Modified Eagle’s 
Media (DMEM) (Invitrogen, Carlsbad, CA), supplemented with 10% feta bovine serum 
(Sigma, St. Louis MO) or 10% bovine calf serum (Hyclone, Logan, Utah), penicillin (100 
U/mL) (Invitrogen) and streptomycin (100 µg/mL) (Invitrogen), respectively in a humidified 
incubator with 5% CO2 at 37 °C. Human umbilical vein endothelial cells (HUVEC) were 
obtained from UNC Tissue Culture Facility and cultured in HuMEC basal medium 
(Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum, bovine pituitary 
extract (Invitrogen, Carlsbad, CA) and HuMEC Supplement (Invitrogen, Carlsbad, CA).
Primary antibodies used for western-blot analysis and immunostaining included rabbit anti- 
fibronectin, anti-alpha-smooth muscle actin (αSMA), anti-fibroblast activation protein alpha 
(FAPα), GAPDH, anti-E cadherin and anti-N cadherin polyclonal antibodies (Abcam, 
Cambridge, MA), rabbit anti-beta catenin monoclonal antibody (Abcam, Cambridge, MA), 
rat anti-CD31 polyclonal antibody (Abcam, Cambridge, MA) and mouse monoclonal 
poly(ADP-ribose) antibody (PARP, Santa Cruz biotechnology, Inc.), rabbit polyclonal anti-
Wnt16 antibodies (Santa Cruz biotechnology, Inc.). Secondary antibodies used for western-
blot analysis and immunohistochemistry staining (IHC) included bovine anti-rabbit IgG-
HRP, rabbit anti-mouse IgG-HRP (Sigma). And secondary antibodies used for 
immunofluorescence staining consists of FITC, Alexa Fluor ®555 and Alexa Fluor ®647 
conjugated anti-rabbit and rat antibodies (Abcam, Cambridge, MA).
Female athymic Balb/C nude mice of 6–8 weeks old were provided by the University of 
North Carolina animal facility. Animals were raised in the Center for Experimental Animals 
(an AAALAC accredited experimental animal facility) at the University of North Carolina. 
All animal handling procedures were approved by the University of North Carolina at 
Chapel Hill’s Institutional Animal Care and Use Committee.
2.1 Preparation of Cisplatin NP
Cisplatin NP were formulated as previously described.26, 27, 34 Briefly, 300 µL of 200 mM 
cis-[Pt(NH3)2(H2O)2](NO3)2 and 300 µL of 800 mM KCl aqueous solution were separately 
dispersed in a mixed oil solution cyclohexane/ triton-X100/hexanol (75:15:10, V:V:V) and 
cyclohexane/Igepal CO-520 (71:29, V:V) to form a well-dispersed reversed micro-emulsion. 
Then, 500 µL of DOPA (20 mM) was added to the cisplatin precursor emulsion and the 
mixture were stirred for 20 min. Afterwards, the two emulsions were mixed and reacted for 
another 20 min. Forty mL of ethanol was then added to break the micro-emulsion and 
particles were collected by centrifuge at 10,000g for at least 15 min. The pellets were 
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washed with ethanol twice to completely remove the surfactants and cyclohexane, and then 
re-dispersed in 2.0 mL of chloroform for storage. Finally, the preparation of cisplatin NP 
consisted of mixing 1 mL of cisplatin nanocores with 200 µL of 20 mM DOTAP/Cholesterol 
(1:1), with 20 µL of 20 mM DSPE-PEG-2000 or 20 µL of 20 mM DSPE-PEG-2000/DSPE-
PEG-AA (4:1).33 After evaporating the chloroform, the residual lipid was dispersed in 100 
µL of 5% glucose. The particle size of cisplatin NP was confirmed using a Malvern 
ZetaSizer Nano series (Westborough, MA). TEM images of LPC NP were acquired using a 
JEOL 100CX II TEM (JEOL, Japan). Cisplatin NP were negatively stained with 2% uranyl 
acetate.
2.2 Preparation of siWnt NP
siWnt NP were prepared through a stepwise self-assembly process based on a previously 
well-established protocol.32 Briefly, cholesterol and DOTAP (1:1, mol/mol) were dissolved 
in chloroform and solvent was removed by rotary evaporator. The lipid film was then 
hydrated with distilled water to make the final concentration of 10 mmol/L cholesterol and 
DOTAP, respectively. Then, the liposomes were sequentially extruded through 400 nm, 200 
nm, 100 nm, and 50 nm polycarbonate membranes (Millipore, Billerica, MA) to form 70–
100 nm unilamellar liposomes. The siWnt NP polyplex cores were formulated by mixing 
140 µL of 36 µg protamine in 5% glucose with equal volume 24 µg siRNA and 24 µg HA in 
5% glucose. The mixture solution was incubated at room temperature for 10 min and then 
60 µL cholesterol/ DOTAP liposomes (10 mmol/L each) was added. Post insertion of 15% 
DSPE-PEG and DSPE-PEG-AA were further performed at 50 °C for 15 min. The size and 
surface charge of the NP were determined by Malvern ZetaSizer Nano series (Westborough, 
MA). TEM images were acquired using a JEOL 100 CX II TEM (JEOL, Japan). Particles 
were negatively stained with uranyl acetate.
2.3 Cell Treatments with Cisplatin for Induction of Wnt16
NIH3T3 fibroblasts were grown until 80% confluent in a six well plate and activated with 10 
ng/mL TGFβ. Two h later, free cisplatin at concentration of 5 µM, 10 µM, 15 µM and 25 µM 
was added to the activated NIH3T3 and treated for another 3h before replacing into fresh 
full DMEM medium and continue incubating for pre-determined time. After treatment, the 
cells were rinsed 3× with PBS and proceeded to Western-blot assay for the analysis of 
Wnt16 protein level in the cells.
2.4 Western Blot Analysis
SRBC tumor samples, UMUC3 cells or NIH3T3 cells were lysed with a Radio-
Immunoprecipitation Assay (RIPA) buffer supplemented with 1% protease inhibitor cocktail 
(PIC). Protein concentration in the tumor or cell lysate was determined using bicinchoninic 
acid (BCA) protein assay reagent according to the manufacturer’s instruction (Invitrogen). 
After dissolved, diluted, reduced and separated by 4–12% SDS-PAGE electrophoresis 
(Invitrogen), the proteins were then transferred to polyvinylidene difluoride (PVDF) 
membranes (Bio-Rad). Membranes were blocked with 5% bovine serum albumin (BSA). 
Then the target proteins were probed with primary antibodies (1:500 dilution), followed by 
the horseradish peroxidase-conjugated secondary antibodies (1:4,000) respectively, and 
detected using the Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, 
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Rockford, IL). The relative protein expression level was quantified with Image J software 
(National Institutes of Health, Bethesda, MD) using GAPDH as a loading control.
2.5 In vitro Transfection
2×105 UMUC3 cells or NIH3T3 cells were seeded into six-well plates per well. NIH3T3 
cells were activated with 10 ng/mL TGFβ2h prior to NP treatment. Then LPH NP loaded 
with siRNA against mouse Wnt16 (siWnt NP) or control siRNA (siCont NP) were added to 
each well in the presence of OptiMEM medium with final concentration of 250 nmol/L. 
Four h after transfection, medium was washed and cells were treated for 3h with 10 µM 
cisplatin to boost the expression of Wnt16. The medium was then replaced with full medium 
and the cells were continued to be incubated overnight. The Wnt16 protein expression levels 
of samples after transfection were determined by western-blot analysis with GAPDH as 
loading control.
2.6 β-catenin Nucleus Translocation Assay
β-catenin assay was carried out to determine the canonical Wnt pathway activation in the 
neighboring UMUC3 cells by Wnt16 secreted from damaged fibroblast.35 A non-contact co-
culture system was first established, with the upper chamber seeded with activated NIH3T3 
subjected to siCont NP, siWnt NP followed by cisplatin NP treatment according to the 
procedure described above.36 Co-culture was initiated when putting the NIH3T3 inserts into 
a 24 well plate with UMUC3 seeded on a coverslip (Fishier Scientific). At indicated time 
points, coverslips were taken out, fixed, permeabilized, blocked and probed with anti-β-
catenin antibody. Cells were further incubated with FITC-labelled secondary antibody and 
then counterstained with Hoechest 33342 (Invitrogen). Images were taken by using a 
confocal microscope (Laser Scanning. Zeiss 510 Meta).
2.7 Scratch Assay
The spreading and migration capabilities of UMUC3 cells affected by Wnt16 secreted from 
neighboring fibroblast were assessed in vitro using a scratch wound assay which measures 
the expansion of a cell population on surfaces.37, 38 The non-contact co-culture system was 
established with NIH3T3 in the upper chamber and UMUC3 in the bottom chamber of a 24-
well plate. The upper chamber NIH3T3 was activated and treated with siCont NP, siWnt 
NP, siCont NP/ cisplatin and siWnt NP/cisplatin according the procedure described above. 
A linear wound was generated in the monolayer of UMUC3 with a sterile 200 µl plastic 
pipette tip upon co-culture. Any cellular debris was removed by washing with PBS and 
incubated with OptiMEM medium for 20 h at 37 °C with 5% CO2. Three representative 
images from each well of the scratched areas under each condition were photographed to 
estimate the relative migration cells. The data were analyzed using Image J. The 
experiments were performed at least in duplicate.
2.8 Lentiviral Luciferase Reporter Assays
The activation of Wnt pathway in the neighboring naïve fibroblast by damaged fibroblast 
was evaluated using TCF/LEF reporter assay.25 To produce stable Wnt-reporter cell lines, 
NIH3T3 cells were transduced with the Cignal Lenti TCF/LEF Reporter (luc) kit for 48h. 
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Following transduction, the cells were cultured under puromycin selection to generate a 
homogenous population of transduced cells. Activated NIH3T3 and Wnt-reporter cell lines 
were seeded on to the upper chamber and lower chamber of the non-direct contact co-culture 
system respectively. The upper chamber received different treatments as previously 
mentioned. Four h post co-culture, bottom cells were collected and luciferase assays were 
performed using a Luciferase Assay Kit (Promega, Inc.) according to the manufacturer's 
instruction.
2.9 Tube Formation Assay
The effect of Wnt16 secreted from damaged fibroblast in inducing angiogenesis in 
neighboring endothelial cells was evaluated by tube formation assay.39, 40 The non-contact 
co-culture system was established with the upper chamber of activated NIH3T3 receiving 
different treatments and bottom chamber of HUVEC in a 24 well plate. For the formation of 
capillary-like structures, 24 well plate were pre-coated using growth factor-reduced matrigel 
(BD biosciences, San Jose, CA, USA). HUVECs (4×104 cells/well) were plated on top of 
matrigel (280 µL/well). Four h after co-culture, HUVECs were stained by calcein AM 
(Invitrogen) and visualized under a fluorescence microscope. The number of tubes were 
quantified by Image J from 5 randomly selected microscopic fields.
2.10 Analyses of Cell Proliferation and Chemotherapy Resistance
All assays were performed at least 3 times and reported as mean values. Assays of cell 
proliferation were performed with the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide (MTT) assay with signals captured using a 96-well plate reader. To assess the 
influence of Wnt16 across a range of cisplatin concentrations, UMUC3 were cultured with 
recombinant Wnt16 protein (R&D systems) at different concentrations (0.03, 0.3, 3, 6, 12 
µg/mL) 6 h prior to cisplatin treatment. Then, cisplatin at a range of concentrations 
bracketing cell line’s IC50 was added to the medium and incubated for 48h. Cell viability 
was assayed by MTT. Nonlinear regression curves were plotted using GraphPad Prism. 
Chemo resistance of bladder cancer cells induced by Wnt16 secreted from fibroblast were 
performed using UMUC3 cultured with either DMEM, or conditioned medium (CM) 
generated from active fibroblasts under different treatments (including treatment with siCont 
NP, siWnt NP, siCont NP/cisplatin, siWnt NP/ cisplatin, cisplatin). The cultured cells 
received cisplatin treatment for 2 days in the CM with cisplatin at concentrations near 
UMUC cell line’s IC50 (10 µM). Cell viability was then assayed, and the percentage of 
viable cells was calculated by comparing each experiment to UMUC3 treated from CM of 
normal activated NIH3T3 cells. Each assay was repeated a minimum of 3 times with results 
reported as mean ± SD. For short-term proliferation assay of fibroblast to cisplatin and 
siRNA treatment, 96-well plates were seeded with 3×103 cells per well NIH3T3 and 
activated 2h prior to treatment with 10 ng/mL TGFβ. Then, cells were transfected with 
siWnt NP or siCont NP at different concentrations, or equivalent concentration to 250 nM 
siRNA. Four h later, cells were washed with PBS and changed into fresh medium or 
cisplatin at a range of concentration bracketing its IC50. Forty-eight h later, cells were 
subject to MTT assay described elsewhere.
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2.11 Establishment of a non-contact co-culture assay
Co-culture assay was established according to a previous protocol with little adjustment.36 
Briefly, NIH3T3 were seeded into a Transwell filter (polycarbonate membrane insert, 0.45 
µm pore, Corning Inc.). Before co-culture, UMUC cells, HUVEC cells or naïve NIH3T3 
cells were plated onto the bottom of either 6 well, 12 well or 24 well plate at determined 
density for different experimental purpose. Diameter of NIH3T3 inserts was also chosen 
accordingly to the size of the well plates. The next day, Transwell insert received different 
types of treatment. After extensively washing away the reagent-containing medium, fresh 
medium was added and co-cultured was started by setting the insert on the cell seeded 
plates. After determined time of co-culture, bottom cells were collected for western-blot 
analysis, β-catenin nucleus translocation assay, tube formation and other 
immunofluorescence assay.
2.12 Tumor Growth Inhibition Assay
A stroma-rich bladder cancer model (SRBC) were established as previously reported with 
little modification.29, 41 In brief, UMUC3 (5×106) and NIH 3T3 (2.5×106) in PBS were 
subcutaneously co-inoculated into the right flank of mice with Matrigel (BD biosciences, 
CA) at a ratio of 1:1 (V/V). Small tumor treatments were initiated on the 9th day when the 
inoculated tumor volume reached 150~200 mm3. Mice were then randomized into 5 groups 
(n=5~7 per group) as follows: Untreated group (PBS), siCont NP, siWnt NP, cisplatin NP, 
siWnt NP/ cisplatin NP. IV injections were performed every other days for a total of 5 
injections with siRNA dose of 0.6 mg/kg (equivalent to 12 µg siRNA per mice) and cisplatin 
dose of 1.0 mg/kg. Tumor volume was measured every day with a digital caliper (Thermo 
Fisher Scientific, Pittsburg PA) and body weight was also recorded. Tumor volume was 
calculated as (1/2*length*length*width). Mice were sacrificed one day after the last 
injection and tumor tissues were collected for further study.
To evaluate the combinatory efficacy on the large tumor, treatments were initiated 14 days 
post inoculating, when tumor volume reached ~700 mm3 in size. Mice were then 
randomized into 4 groups (n=5) subjected to the following treatments: PBS, siWnt NP, 
cisplatin NP and siWnt NP/cisplatin NP respectively. IV injections were performed every 
day (siRNA 0.6 mg/kg and cisplatin 1.0 mg/kg) with total 4 treatments. Tumor volume and 
body weight were continuously monitored for another week post last injection to determine 
combination effect on tumor regression and resistance. Mice in the PBS groups were 
sacrificed when tumor volume reached ~2,000 mm3.
2.13 In vivo nanoparticle penetration and distribution study
For the study of NP penetration, two types of NP were prepared as follows: firstly, DiI 
labeled cisplatin NP were prepared by mixing 2% DiI with DOTAP, cholesterol and 
cisplatin nanocores to formulate the final NP. Secondly, DiI labeled liposomes were 
prepared by mixing 2% DiI into the lipid membrane and followed by sequential extrusion. 
The GFP labeled NIH3T3 SRBC models were established as described in the 
Supplementary Information. Mice were subjected to different treatments. One day post 
injection, mice were administrated with DiI labeled cisplatin NP or liposomes at a dose of 
0.1 mg/kg DiI and were sacrificed 8h post IV injection. Fresh tumor tissues were collected 
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and dissociated as mentioned above. The ratio of cells that took up DiI and ratio of GFP 
labeled fibroblast that took up DiI were analyzed and quantified by flow cytometry with a 
BD FACSAria instrument (Beckon Dickinson). For the localization and visualization of NP 
penetration, tumor was further frozen and sectioned. Frozen tumor sections were fixed with 
cold methanol for 15 min and 1% triton for 5 min, double stained with CD31 and αSMA 
primary antibodies at 4°C overnight followed by incubation with FITC-labeled secondary 
antibody for 1h at room temperature. The sections were also directly stained with DAPI and 
covered with a coverslip. The sections were observed using a Nikon light microscope 
(Nikon Corp., Tokyo). Five randomly selected microscopic fields were quantitatively 
analyzed by using Image J software.
2.14 Immunohistochemical Staining (IHC) and Immunofluorescence Staining (IF)
IHC of Wnt16. IHC was performed using a standard streptavidin-biotin-peroxidase 
complex method as previously reported.42 In brief, one day post the small tumor inhibition 
study on SRBC model, tumor tissues were collected and processed for paraffin sections. 
Paraffin block sections of SRBC with different treatments were then deparaffinized, antigen 
recovered, blocked and probed with Wnt16 primary antibody (1:100 dilution) at 4 °C 
overnight, and then detected using a rabbit specific HRP/DAB detection IHC kit as 
recommended by the manufacturer (Abcam, Cambridge, MA). Cell nuclei were counter-
stained with hematoxylin. Percentage of Wnt16 coverage were quantified by using Image J 
on 5 representative microscopic fields. TUNEL assay. Paraffin-embedded tumor sections 
was deparaffinized and rehydrated. The slides were then stained using a TUNEL assay kit 
(Pierce) according to the manufacturer’s instruction. Masson Trichrome Staining. Paraffin-
embedded tumor sections was deparaffinized and rehydrated. The slides were then stained 
using a Masson Trichrome Kit (St. Louis, MO) according to the manufacturer's instruction. 
IF. Paraffin embedded tissues were prepared by the UNC Tissue Procurement Core and the 
slices were deparaffinized, antigen recovered, permeabilized and fixed if necessary, and 
blocked with 1% BSA at room temperature for 1h. Cell markers were detected with 
antibodies conjugated with fluorophores as indicated. Images were taken using fluorescence 
microscopy. For the purpose of double staining, primary antibodies with different species 
origins were applied and different secondary antibodies with non-overlap fluorophores were 
adopted. For the immunofluorescence staining of in vitro cell samples, cells were fixed with 
2% PFA for 15 min, washed, permeabilized, and processed for staining with the same 
protocol as the in vivo tumor samples. Confocal microscopic images were taken accordingly 
(Laser Scanning. Zeiss 510 Meta).
2.15 Statistical analysis
Statistical analysis was undertaken using Prism 5.0c Software. A two-tailed t-test or a one-
way analysis of variance was performed when comparing two groups or more than 2 groups, 
respectively. Statistical significance was defined by a value of p < 0.05.
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3. Results and Discussion
3.1 Off-target distribution of cisplatin NP to TAF induces tumor cells resistance via 
secretion of Wnt16
We have prepared cisplatin NP according to a previous protocol with little adjustment.34 As 
shown in Fig. 1a, cisplatin NP significantly inhibited growth of a stroma-rich bladder cancer 
model (SRBC) at a low dose (1 mg/kg) compared with free cisplatin. However, after 
multiple injections, relapse and resistance occurred in the cisplatin NP treated group. To 
determine the underlying mechanism of acquired-resistance to cisplatin NP treatment, we 
examined tissues collected after multiple PBS or cisplatin NP exposures, and observed an 
elevated levels of Wingless-type MMTV integration site family, member 16 (Wnt16) in the 
cisplatin NP treated SRBC tumors (Fig. 1b) but not tumors treated with PBS or free 
cisplatin. Abnormal Wnt signal activation has been shown to promote tumorigenesis, 
stemness and resistance in various tumors.43, 44 Among the Wnt family members, Wnt16 is 
a major secreted factor generated in response to DNA damage.9, 17 Though little information 
has linked Wnt signaling to cisplatin induced resistance, a previous study demonstrated that 
Wnt16 expression was induced in prostate and breast cancer fibroblasts in response to 
chemotherapy-induced DNA damage resulting in cancer cell resistance.9, 45
The basal-like molecular subtype of bladder cancer has been correlated with increased 
stromal content and patients with basal-like bladder cancer have a worse overall survival 
than those with the luminal subtype.46, 47 Interestingly, basal-like bladder tumors have 
increased levels of Wnt16 (Fig. 1c), indicating a role of Wnt16 in facilitating the progression 
and resistance of bladder cancer. To examine if Wnt16 is a cause of cisplatin resistance in 
basal type bladder cancer, we tested the ability of recombinant Wnt16 protein to induce 
cisplatin resistance in vitro (Fig. 1d). The IC50 of cisplatin to basal type UMUC3 cells 
continually increased from 12.4 to 30 µM as the concentration of Wnt16 was increased from 
0 to 12 µg/mL (Fig. 1d). To evaluate whether the effective concentration of Wnt16 that 
induced cisplatin resistance in vitro (Fig. 1d) was physiologically relevant, we quantified the 
concentration of Wnt16 upregulated by cisplatin NP in vivo. Wnt16 concentrations in 
cisplatin NP treated tumors (approximately 6.5 µg/ml) was well within the range of 
concentrations of Wnt16 that were sufficient to induce cisplatin resistance (Fig. 1d and 
Supplementary Fig. S2). Thus, cisplatin NP treatment induced Wnt16 secretion, leading to 
chemotherapy resistance of tumor cells.
Tumors are heterogeneous, therefore we next sought to determine the cellular origin of 
Wnt16 production within tumors. Wnt16 expression has been detected on uterine stroma and 
was overexpressed by DNA damaged stromal cells surrounding prostate tumors.9, 48 To 
examine whether stromal cells were responsible for Wnt16 upregulation in our SRBC 
model, we treated the major cellular components of the SRBC model (UMUC3 cells and the 
mouse fibroblast NIH3T3) in vitro with cisplatin. In order to mimic in vivo TAF, NIH3T3 
was pre-conditioned with TGF-β to obtain a TAF-like phenotype. We found elevated 
amounts of Wnt16 in both cell lysate and conditioned medium from TGF-β activated 
NIH3T3 cells after exposure to either free cisplatin or cisplatin NP treatment (Fig. 1e). In 
contrast, Wnt16 expression was not induced in UMUC3 cells or other epithelial cancer cell 
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lines (Fig. 1e and supplementary Fig. S3). To further confirm the origin of the upregulated 
Wnt16 level in vivo, a UMUC3 tumor model was developed without the addition of 
NIH3T3. This model showed a low TAF level. Cisplatin NP failed to induce Wnt16 in the 
UMUC3 model further indicating the TAF-origin of Wnt16 (supplementary Fig. S4). The 
fact that Wnt16 upregulation is not the result of exogenously added NIH3T3 fibroblasts 
comes from the observation that a patient derived xenograft model of human bladder cancer 
also responded to repeated cisplatin NP challenges by upregulating Wnt16 (supplementary 
Fig. S5). Therefore, consistent with previous reports, our studies confirm that cisplatin 
induces Wnt16 in TAF, rather than cancer cells. To evaluate the intratumoral distribution of 
cisplatin NP and in particular its relationship with increased expression level of Wnt16, 
cisplatin NP were labeled with DiI and intravenously (IV) injected into SRBC model mice. 
Flow cytometry was used to quantify DiI particle uptake in different cell types in the SRBC 
model 8h after injection. As shown in Fig. 1g, approximately 23.3% of TAF internalized DiI 
NP. The distribution of DiI NP was further confirmed by immunofluorescence staining of 
different intratumoral cell types. We saw TAF located in close proximity to blood vessels 
were able to take up cisplatin NP (Fig. 1f), indicating that cisplatin NP, which were 
originally designed to target tumor cells, could off-targetedly distribute to fibroblast cells. 
Western-blot analysis further confirmed the expression of sigma-receptors on activated 
TAF, which explained the positive internalization of cisplatin NP by TAF (Supplementary 
Fig. S6). Since Wnt16 was reported as a secreted factor in response to damage9, we next 
evaluated whether cisplatin NP induced TAF’ damage and consequently leading to Wnt16 
secretion. We observed that, after multiple injections, cisplatin NP were able to induce 
apoptosis in both TAF and tumor cells with approximately half of the apoptotic cells being 
TAF (Fig. 1h). Therefore, we conclude that cisplatin NP are taken up by TAF, inducing 
apoptosis and the secretion of Wnt16 to promote (in a paracrine fashion) cisplatin resistance 
in tumor cells.
3.2 Wnt16 knockdown inhibits growth and invasion of neighboring bladder cancer cells
We hypothesized that the combined delivery of cisplatin NP along with siRNA targeting 
Wnt16 to fibroblasts would lead to enhanced anti-tumor efficacy. We encapsulated siRNA 
against Wnt16 into liposome-hyaluronic acid- protamine nanoparticles (LPH NP) as 
previously described (siWnt NP) (Supplementary Fig. S1).32 In order to improve fibroblast 
internalization and ensure we were knocking down Wnt16 in the fibroblast population and 
not the UMUC3 cells, we took the following into consideration: firstly, anisamide was 
conjugated onto LPH to improve its internalization, since TAF also express high levels of 
sigma receptor (Supplementary Fig. S6). Secondly, since the fibroblast cells are of mouse 
origin and the cancer cells are of human origin, we used mouse specific siRNA (with four 
mismatches with the human sequence) to increase the selectivity for Wnt16 knockdown. 
Based on these assumptions, as expected, we confirmed that LPH NP loaded with mouse 
anti-Wnt16 siRNA was able to decrease cisplatin induced Wnt16 protein levels in activated 
NIH 3T3 cells but did not have any effect in UMUC3 cells (Supplementary Fig. S7), 
confirming that siRNA delivered by LPH NP could specifically knockdown mouse, but not 
human, Wnt16. To confirm that the effects of Wnt16 knock-down were working in a 
paracrine manner, conditioned medium from fibroblasts with different treatments were 
added to cisplatin (10 µM) treated UMUC3 cells. As expected, conditioned medium from 
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cisplatin treated fibroblasts showed 1.2–1.5 fold (p<0.05) higher activity in protecting 
UMUC3 cells from cisplatin induced cell death compared to conditioned medium without 
cisplatin treatment. Such activity was abolished if the fibroblasts were also treated with 
siWnt NP (Fig. 2a). These experiments indicate that Wnt16 secreted from cisplatin damaged 
fibroblasts is both necessary and sufficient to induce resistance in a paracrine manner in 
neighboring cancer cells.
We next sought to determine the possible mechanisms. A non-contact co-culture system of 
NIH3T3 and UMUC3 was established using a Transwell configuration (Fig. 2b).36 Previous 
studies indicated that the secreted Wnt16 mainly activates the canonical Wnt/β-catenin 
pathway.9, 49 In an attempt to confirm that the Wnt/β-catenin signaling pathway in UMUC3 
cells was activated by the Wnt16 secreted from cisplatin treated fibroblast in the upper 
chamber, immunofluorescence was used to visualize β-catenin localization in UMUC3 cells 
in the lower chamber at different time points after co-culture.35 As shown in Fig. 2d, β-
catenin was primarily membranous during the initial 2h of co-culture, however, cisplatin NP 
treated NIH3T3 cells promoted both increased β-catenin abundance but also nuclear 
localization in UMUC3 cells particularly at 4h after co-culture. As expected, siWnt NP 
treatment of fibroblasts prohibited nuclear translocation of β-catenin in the UMUC3 cells. In 
addition, known β-catenin downstream targets, including c-Myc and Cyclin-D1, were 
significantly up-regulated in the cancer cells co-cultured with cisplatin treated fibroblasts 
(Fig. 2e).50, 51 The expression of these two proteins slightly decreased after co-culturing 
with fibroblasts with treated siWnt NP alone or in combination with cisplatin. Control 
siRNA NP (siCont NP) and human specific siRNA NP were set as controls and no 
biological function was found.
We then studied the paracrine function of Wnt16 on tumor cells. Apoptotic responses 
measured by cleavage of the major apoptotic protein PARP were investigated and further 
indicated that co-culture of UMUC3 cells with cisplatin treated NIH3T3 cells substantially 
attenuated cisplatin induced apoptosis (Fig. 2e). The Wnt signaling pathway is known to 
enhance cell motility and invasiveness via epithelial-mesenchymal transition (EMT).9, 35 
Recently, EMT has been considered to be one of the major mechanisms for cisplatin induced 
resistance in pancreatic cancer.52 Loss of E-cadherin and gain of N-cadherin expression are 
the main characteristics of EMT.9 When the lower chamber UMUC3 cells were exposed to 
cisplatin treated NIH3T3 cells in the upper chamber, E-cadherin was downregulated and N-
cadherin was upregulated consistent with EMT in UMUC3 cells. This EMT phenotype was 
abolished when UMUC3 cells were exposed to siWnt NP treated fibroblasts (Fig. 2e). EMT 
is also an indication of tumor cell mobility. A scrape assay was performed to evaluate the 
mobility of cells using the same non-contact co-culture system. Twenty h after co-culture, 
NIH3T3 cells treated with cisplatin enhanced the mobility of neighboring UMUC3 cells in 
the lower chamber, while Wnt16 downregulation in the upper fibroblasts could inhibit this 
movement (Fig. 2c).
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3.3 Wnt16 knockdown modulates the biological function of neighboring TAF and their 
sensitivities to cisplatin
TAF not directly treated by cisplatin NP (hereafter referred to as naïve TAF) were also 
affected by paracrine Wnt16 secreted from cisplatin treated fibroblasts. To determine if Wnt 
signaling was activated in the neighboring naïve TAF, we generated an activated NIH3T3 
cell strain with stable expression of Wnt reporter using a Cignal Lenti T cell factor/lymphoid 
enhancer binding factor (TCF/LEF) Reporter Kit and seeded these cells on the lower 
chamber of the non-contact co-culture system (Fig. 2f). Results indicated that cisplatin 
treated TAF in the upper chamber of the system could activate the canonical Wnt signaling 
in the lower chamber naïve fibroblasts (Fig. 2g). Enhanced luciferase intensity was observed 
4h after co-culture, which was temporally consistent with the fibroblasts in the lower 
chamber stimulated directly by Wnt16 recombinant protein. siWnt, but not siCont, NP 
suppressed the expression of Wnt16 and completely blocked the activation of β-catenin 
signaling (Fig. 2g). Fibronectin is secreted from functional TAF and has been shown to 
increase extracellular matrix (ECM) rigidity and promote tumor malignancy.53 Since 
fibronectin expression is closely regulated by the canonical β-catenin mediated Wnt 
pathway, fibronectin levels can serve as an important indicator to evaluate the relationship 
of Wnt16 knockdown on ECM remodeling.54 We found that fibronectin levels were 
upregulated in cisplatin treated naïve fibroblasts relative to the untreated fibroblasts (Fig. 
2h). Moreover, siWnt16, but not siCont, NP treatment in the upper chamber cells inhibited 
the expression of fibronectin of naïve TAF in the lower chamber (Fig. 2h). This observation 
was further confirmed by immunofluorescence staining of fibronectin in the lower chamber 
(Fig. 2i). Finally, an MTT assay was carried out to show that a deficiency of Wnt16 did not 
influence the cell viability of the activated fibroblasts (Fig. 2j). This finding further 
confirmed that Wnt16 protein did not play a pro-proliferative or pro-apoptotic role in 
regulating fibroblasts growth, but rather protects the cells from cisplatin induced cell death. 
In keeping with this notion, the combination treatment of activated fibroblasts with siWnt, 
but not siCont NP, and cisplatin facilitated cell death (Fig. 2k).
3.4 Single dose cisplatin NP attenuates TME function and improves NP penetration
Based upon our in vitro results, we hypothesized that while cisplatin NP taken up by TAF 
leads to rapid fibroblast death.30, damaged fibroblasts could promote the survival of 
surviving TAF. To confirm that cisplatin could remodel the TME in vivo, single dose and 
multiple dose siCont NP/cisplatin NP treatments were carried out in our SRBC model 
(siCont NP were set as control for siWnt NP treatment and showed no therapeutic 
interference, and thereafter, instead of mentioning siCont NP/cisplatin treatment, we directly 
referred to it as cisplatin NP treatment). Both tumor growth dynamics and NP distribution 
kinetics were monitored. Consistent with a previous study by Zhang et al, a single dose of 
cisplatin NP was efficient in remodeling the TME for improved NP penetration and 
therapeutic outcome.29 Representative immunostaining images in Fig. 3a showed that 
cisplatin NP significantly reduced the expression level of fibronectin and α-smooth muscle 
actin (SMA) (a marker of TAF activation) relative to control treatment (siCont NP). 
Fibronectin facilitates the deposition and crosslinking of collagen and elastin.53, 55 
Therefore, consistent with decreasing fibronectin, both collagen content and collagen 
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crosslinking were reduced in the cisplatin NP treated groups (Fig. 3a and b). The changes in 
expression levels of major ECM proteins were further confirmed by western blot (Fig. 3c).
We next sought to determine the influence of TAF on ECM remodeling after a single dose 
cisplatin NP therapy. A SRBC model was developed by co-inoculating a green fluorescence 
protein (GFP) labeled NIH3T3 cells with UMUC3 cells. Notably, survival of GFP+ 
fibroblasts decreased significantly in the cisplatin NP treated group compared to other 
treatment groups (Fig. 3d). This result suggested that a single dose of cisplatin NP could 
significantly deplete TAF, reducing the secretion of ECM proteins and effectively disrupting 
the ECM structure. Based on previous studies of the tumor interstitial matrix, we further 
hypothesized that a decrease in collagen content would improve the intratumoral distribution 
of NP.7, 56 Therefore, we quantitatively measured the intratumoral distribution of DiI-
labeled liposomes (70 nm in diameter) in the SRBC model with the aforementioned single 
dose treatments via flow cytometry. Consistent with our hypothesis, an improved NP 
accumulation and penetration was observed in the cisplatin NP treated group compared to 
the control group (siCont NP) (Fig. 3e). Improved NP penetration was an indication of better 
therapeutic effect. Since naïve tumors maintained a basal level expression of Wnt16, single 
dose of siWnt NP could also improve NP penetration and tumor inhibition effect. Instead of 
depleting TAF, downregulation of Wnt16 decreased the expression of α-SMA and 
fibronectin, consequently reducing the content of collagen (Fig. 3a, b). Combinatory 
cisplatin NP and siWnt NP treatment was slightly more effective than single cisplatin NP 
treatment alone (Supplementary Fig. S9).
3.5 siWnt NP overcome the cisplatin NP induced TME stiffening after multiple doses and 
improve the overall NP accumulation
Although a single dose of cisplatin NP demonstrated efficient killing in both tumor cells and 
TAF, the tumor still relapsed after repeated treatments (Fig. 1a). The resistant phenotype 
was acquired in both tumor cells and neighboring TAF (Fig. 4a and c). To examine the 
acquired resistance in TAF and the TME, the SRBC models were dosed multiple times of 
cisplatin NP or siWnt NP. After 4 doses, the Wnt16 expression level was significantly 
elevated in the cisplatin NP group (Fig. 4c). Consistently, expression of α-SMA, fibroblast 
activation protein α (FAPα) and fibronectin were also elevated (Fig. 4a, b and c). Collagen 
content was also upregulated after multiple cisplatin NP treatments (Fig. 4a and b). Notably, 
these changes in the TME after repeated dosing was different from the changes in the single 
dose treatment, which showed a decrease in TAF and the ECM. This trend indicates the 
gradual development of acquired resistance in the TME. The resistance of TAF to cisplatin 
NP after multiple doses was assessed by quantitative analysis of the GFP+ fibroblast 
percentage in residual tumors by flow cytometry. In contrast to the decreasing of GFP+ cell 
ratio found in the single dose cisplatin NP treatment (Fig. 3d), the survival ratio of GFP+ 
fibroblasts increased by ~2-fold after repeated cisplatin NP dosing (Fig. 4d). Consequently, 
the content of cisplatin in the residual tumor remained at almost the same level with that of 
single dose (Fig. 3f and Fig. 4f). Conversely, both multiple dose siWnt NP and siWnt NP/
cisplatin NP treatments inhibited the changing of the TAF ratio in the tumor and remodeled 
the TME by significantly decreasing α-SMA, FAPα, fibronectin and collagen content (Fig. 
4a and c). Notably, the combination of cisplatin NP with siWnt NP could reverse the 
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cisplatin induced resistance, increase DiI labeled liposome penetration by ~2-fold (Fig. 4e), 
and promote the accumulation of cisplatin by ~3-fold (Fig. 4f).
3.6 Wnt16 knockdown attenuates cisplatin NP induced angiogenesis
A recent study showed that a plasmid-encoding Wnt16 gene accelerated tube formation in 
cultured primary mouse cavernous endothelial cell (MCECs), suggesting a role in cavernous 
angiogenesis.57–59 Therefore, we further hypothesized that knockdown of Wnt16 could also 
inhibit angiogenesis. Data in our study showed that both Wnt16 secreted from NIH3T3 
fibroblasts (using the non-contact co-culture system) and recombinant Wnt16 protein 
induced tube formation of human umbilical cord vascular endothelial cells (HUVECs) (Fig. 
5a, b and Supplementary Fig. S8). Downregulating Wnt16 using siWnt NP also 
downregulated angiogenesis and vascular remodeling in the SRBC model in vivo after 
multiple doses (Fig. 5c, d). Since angiogenesis accelerates tumor progression, it is highly 
likely that the anti-angiogenesis caused by siWnt NP is one of the reasons for its efficient 
tumor inhibitory effect.35 Inhibition of angiogenesis, though, weakens the enhanced 
permeability and retention (EPR) effect and compromises NP-mediated drug delivery 
efficiency.60 However, multiple doses of cisplatin NP/siWnt NP, promoted the penetration 
of both DiI labeled liposomes (Fig. 4e) and cisplatin NP (Fig. 5e, f) compared to the 
cisplatin NP alone group. Decreased stroma density by siWnt16 NP might contribute to the 
improved NP penetration. In addition, siWnt NP treatment might prune immature vessels 
and remodels the vasculature to more closely resemble the structure of normal vessels. This 
so-called “tumor vessel normalization” not only benefits the delivery of small molecule 
chemo drugs to tumors, but also benefits the accumulation of soft NP like liposomes (less 
than 100 nm) and small, solid NP like cisplatin NP. This is consistent with previous findings 
reported by Jain et al and Kataoka et al.60–62
3.7 Intravenous administration of siWnt NP with cisplatin NP effectively inhibited SRBC 
tumor growth at early or late stage
The efficacy of systemically delivering siWnt NP in combination with cisplatin NP was 
evaluated at different tumor stages in the SRBC model. An early stage SRBC model was 
established with tumor sizes around 150–200 mm3 and treatments were given every other 
day (Fig. 6a). Cisplatin NP could partially inhibit tumor growth. Whereas, the combination 
of cisplatin NP and siWnt NP effectively inhibited solid tumor growth (Fig. 6a, p<0.001). 
siCont had no influence on tumor growth, ruling out any effect from the delivery vehicle 
itself. The efficacy was further evaluated on a late-stage SRBC tumor when the tumors 
developed to size around 700 mm3. Daily injections were carried out to ensure a better 
therapeutic outcome. As shown in Fig. 6b, both cisplatin NP and siWnt NP showed a mild 
tumor inhibition effect. However, the combinatory therapy presented potent efficacy in the 
large tumor treatment. It could effectively shrink the tumor and delay tumor growth for 
almost one week after the last injection. No decrease in body weight and no abnormal blood 
parameters were observed in any of the groups (Supplementary Fig. S10–12, Table. S1). To 
demonstrate that tumor growth inhibition in the siWnt NP treated group and the combinatory 
group was the result of Wnt16 downregulation, we measured the level of Wnt16 after 
treatments.
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Immunohistochemistry (IHC) images showed an effective silencing of Wnt16 expression in 
the combination group approximately 4 to 5-fold compared to cisplatin NP treated groups 
(Fig. 6d). Western blot results were consistent with the IHC data (Fig. 6e). In addition, 
siWnt NP could also sensitize SRBC model towards cisplatin NP treatment and lead to 
extensive apoptosis (p<0.05) accounting for the better therapeutic outcome in the 
combinatory treatment (Fig. 6f, supplementary Fig. S13).
4. Conclusions
Our experimental results suggest that off-target distribution of chemotherapeutic NP to TAF 
could lead to contradictory effects. Internalization of cisplatin into TAF resulted in their 
immediate killing, blocking the secretion of stroma factors (e.g. fibronectin) and violating 
the communication between fibroblasts and tumor cells, subsequently inhibited tumor 
growth. However, chronic exposure of TAF to cisplatin activated the damage response 
program and promoted the secretion of survival proteins, such as Wnt16, leading to tumor 
cell resistance and metastasis, stroma reconstruction and angiogenesis (Fig. 6c). Our studies 
underscore the importance of TAF as both biological supporters for tumor growth, 
metastasis as well as a physical barrier for NP penetration and therapeutic outcome. Our 
study provides guidance and implications for the design of tumor-targeted delivery of 
therapeutic NP. We focused on the off-target distribution of NP into non-tumor stroma cells 
and showed the importance of NP stroma distribution in acquired resistance and limited NP 
penetration. Our findings suggest that major survival factors in response to damage play 
significant roles in TAF mediated acquired resistance. Blocking such factors benefits both 
the pharmacological activities as well as the drug delivery efficiency of the NP delivered 
chemodrugs and leads to improved therapeutic outcome. Therefore, exploring the major 
secreted survival factors in tumor-stroma crosstalk and co-delivering two regiments that 
could kill the fibroblasts as well as inhibit the secretion of these major factors would be of 
significant clinical potential. We anticipate our study will serve as a gateway for future 
development of NP to explore the complicated tumor microenvironment. The current study 
also demonstrated the power of nanotechnology for studying the role of TME in 
chemotherapy.
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Figure 1. Off-target delivery of cisplatin NP to TAF induces tumor cells resistance via secretion 
of Wnt16
a. Tumor growth inhibition of free cisplatin and cisplatin NP in a stroma rich bladder cancer 
(SRBC) model (n=5). b. Western blot analysis of Wnt16 protein levels in the resistant 
tumors. Intensity of the protein bands was quantified by using Image J (n=3, * p<0.05, 
Student’s t-test). c. Expression level of Wnt16 in different subtypes of bladder cancer. Data 
were collected and analyzed from The Cancer Genome Atlas (TCGA) database. (* p<0.05, 
one way ANOVA). d. Dose response curves of UMUC3 cells treated with different levels of 
recombinant Wnt16 protein (n=4, * p<0.05, ** p<0.01, one way ANOVA). IC50 of cisplatin 
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in UMUC3 treated with Wnt16 protein was shown in the inserted figure. eIn vitro western 
blot analysis of Wnt16 level in cisplatin treated UMUC3, cisplatin treated activated 
fibroblast NIH3T3 cells and the conditioned medium. f. DiI-labeled cisplatin NP distribution 
in the SRBC tumor. Tumors were collected 8h post DiI-NP injection. Presentative 
fluorescence images of TAF (α-SMA: green), blood vessels (CD31: magenta), and DiI-
labeled NP (red) and nucleus (DAPI: blue) were shown. Scale Bar equates to 100 µm. g. 
Quantification of DiI-NP distribution in TAF by flow cytometry. SRBC model was 
established by co-inoculated UMUC3 with GFP labeled NIH3T3. h. Fluorescence and 
TUNEL staining of the SRBC tumor after multiple cisplatin NP treatments with α-SMA 
(red) and apoptotic cells (green). Yellow square boxes highlight the apoptotic fibroblasts 
(co-stained as yellow). The ratio of apoptotic fibroblasts over all apoptotic cells was 
calculated. Scale Bar is 100 µm.
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Figure 2. Influences of specific Wnt16 knockdown on the neighboring tumor cells and fibroblasts
a. Cell viability (48h) of UMUC3 towards cisplatin (10 µM) when treated with different 
NIH3T3 conditioned medium (CM) (n=4, * p <0.05, ** p<0.01, one way ANOVA). b. A 
non-contact co-culture system was established with the upper chamber seeded with activated 
NIH3T3 of different treatments, and the lower chamber seeded with naïve UMUC3. This 
system was used in the scratch assay, β–catenin translocation assay and western blot. c. 
Scratch assay using the non-contact co-culture system with upper chamber NIH3T3 and 
lower UMUC3. * Moving distance of lower chamber UMUC3 compared to 0h, n=3. Scale 
bar is 100 µm. d. Confocal images of β-catenin nucleus translocation (Scale bars 20 µm) in 
low chamber UMUC3. e. Western blot analysis of Wnt pathway down-stream proteins (c-
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myc and cyclin D1), EMT markers (E-cadherin (E-cad) and N-cadherin (N-cad)) and 
apoptotic marker (cleaved PARP) in the lower UMUC3 chamber. f. A non-contact co-
culture system was established with the upper chamber seeded with activated NIH3T3 and 
the lower chamber seeded with naïve activated NIH3T3. g. Assay of canonical Wnt pathway 
signaling through activation of luciferase labelled fibroblasts was performed in the lower 
chamber. Four h after co-culture, relative luciferase units (RLU) were quantified. Data are 
mean ± SD, n=3. h. Western blot analysis of a major ECM glycoprotein, fibronectin, level in 
the lower chamber 24h post co-culture. i. Confocal images of immunofluorescence staining 
of fibronectin in the lower chambers (fibronectin: green, cell nucleus: blue), scale bar 
represents 20 µm. j. Cell proliferation of activated NIH3T3 transfected with anti-Wnt16 or 
control siRNA at different concentrations (n = 4). k. Viability of activated NIH3T3 across a 
range of cisplatin concentrations with transfection of anti-Wnt16 or control siRNA 
(concentration of siRNA was 180 nM). (n=4, * p<0.05, Student’s t-test). Data points show 
mean ± SD.
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Figure 3. Single dose cisplatin NP attenuate TME function and improve NP penetration
Single dose siCont NP (1), cisplatin NP/siCont NP (2), siWnt NP (3) and cisplatin NP/siWnt 
NP (4) were IV administered to mice separately with cisplatin 1.0 mg/kg and siRNA 0.6 
mg/kg. Tissues were collected 2 days after injections. a. Immunofluorescence staining of 
fibronectin, α-SMA. The nuclei were stained with DAPI (blue) and fibronectin and α-SMA 
were stained red. Another ECM component, collagen, was stained by using Masson 
trichrome. The blue color represents collagen content, while the cytoplasm is stained red. 
Scale bar is 100 µm. b. Quantitative analysis of fibronectin, α-SMA and collagen content 
using Image J from 5 randomly selected microscopic fields. (n=5, * p<0.05; ** p<0.01; *** 
p<0.001, Student’s t-test) c. Western blot analysis of FAP α, α-SMA, fibronectin and Wnt16 
protein levels in the tumors two days after single dose NP treatment. d. NIH3T3 in the 
SRBC model was further labeled with GFP. The ratio of GFP positive TAF was quantified 
by flow cytometry two days after NP treatment. (n=8, *** p<0.001, Student’s t-test) e. DiI-
labeled liposomes (~70nm) were IV injected one day before sacrificing the mice. 
Fluorescent liposome accumulations and penetrations in the SRBC tumors were quantified 
by flow cytometry (n=3, ** p<0.01, Student’s t-test). f. The amount of accumulated 
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platinum in cisplatin NP/siCont NP (2) and cisplatin NP/siWnt NP (4) were measured by 
ICP-MS and shown as ng cisplatin/mg tumor tissue. (n=3, * p<0.05, Student’s t-test). Data 
in all charts show mean ± SD.
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Figure 4. siWnt NP overcome the cisplatin NP induced TME stiffening after multiple doses and 
improve the overall NP accumulation
siCont NP (1), cisplatin NP/siCont NP (2), siWnt NP (3) and cisplatin NP/siWnt NP (4) 
were IV administered to mice separately with cisplatin 1.0 mg/kg and siRNA 0.6 mg/kg, 
every other day for a total of 4 injections. a. Immunofluorescence staining of fibronectin 
(red), α-SMA (red) and cell nucleus (DAPI: blue). Collagen was stained via Masson 
trichrome staining (blue). Scale bar represents 100 µm. b. Quantitative analysis of 
fibronectin, α-SMA and collagen content using Image J from 5 randomly selected 
microscopic fields. (* p<0.05; ** p<0.01; *** p<0.001, Student’s t-test) c. Western-blot 
analysis of FAPα, α-SMA, fibronectin and Wnt16 levels in the tumors 2 days after multiple 
NP treatment. d. NIH3T3 in the SRBC model was further labeled with GFP. The ratio of 
GFP positive TAF was quantified by flow cytometry 2 days after NP treatment. (*** 
indicated p<0.001, Student’s t test, n=8) e. DiI-labeled liposomes (~70nm) were IV injected 
1 day before sacrificing the mice. Fluorescent liposome accumulations and penetrations in 
the SRBC tumors were quantified by flow cytometry (** p<0.01, Student’s t-test, n=3). f. 
The amount of accumulated platinum in cisplatin NP/siCont NP (2) and cisplatin NP/siWnt 
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NP (4) were measured by ICP-MS and shown as ng cisplatin/mg tumor tissue (*p<0.05, 
Student’s t-test, n=3). Data in all charts show mean ± SD.
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Figure 5. Wnt16 downregulation attenuates cisplatin NP induced angiogenesis for bladder 
cancer treatment
A non-contact co-culture study was performed to evaluate tube formation in vitro. The upper 
chamber NIH3T3 cells were given different treatments and co-cultured with HUVEC cells 
seeded in the lower chambers. Tube formation was monitored in HUVEC cells as indicators 
for angiogenesis 4h after co-culture. HUVEC cells were stained by calcium AM (green) (a) 
and the number of formed tubes was calculated (b). Five randomly selected microscopic 
fields were quantitatively analyzed by Image J (* p<0.05, ** p<0.01, *** p<0.001, Student’s 
t-test). Scale bar represents 100 µm. Influence on angiogenesis was further evaluated in vivo 
by immunofluorescence staining endothelial cells with CD31 (red) after multiple treatments 
(c). Quantitative analysis was calculated based on 5 randomly selected microscopic fields (* 
p<0.05, ** p<0.01, Student’s t-tests, scale bar indicates 100 µm) (d). Distribution of DiI 
labeled cisplatin NP 8h after IV injection in different treatments of the SRBC model (e). 
Five images were quantified and the result is shown on right (* p<0.05, ** P<0.01, *** 
P<0.001, Student’s t-tests) (f).
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Figure 6. IV injection of siWnt NP with cisplatin NP inhibited SRBC tumor growth
a. IV injection of siWnt NP with cisplatin NP inhibited SRBC tumor growth when the first 
injection started on day 9 post inoculation (small tumor volume ~150 mm3, n=5–7). Data 
show mean ± SD (** p<0.01; *** p<0.001, ns, no significant difference, one way ANOVA). 
b. IV injection of siWnt NP with cisplatin NP led to tumor regression when the first 
injection started on day 14 post inoculation (large tumor volume ~700 mm3, n=4). c. 
Scheme of the proposed hypothesis. d. Immunohistochemistry staining of Wnt16 on tumor 
tissues at the end point of small tumor inhibition study. Wnt16 was stained brown and the 
cell nuclei were stained blue. The scale bar represents 100 µm. The Wnt16 content of 5 
randomly selected microscopic fields was quantified using Image J. The quantification bar 
chart is shown on right (** p<0.01, *** p<0.001, Student’s t-test). e. Western blot analysis 
of Wnt16 levels in tumors after treatment. Three samples were taken randomly from three 
mice in each treatment group. The intensity of the Wnt16 western band was analyzed by 
Image J and calculated based on content of GAPDH. Quantification is shown on right. * 
p<0.05, Student’s t-test. f. Effect of NP on the SRBC model apoptosis using TUNEL assay. 
Five images were quantified and the data is shown on right (* p<0.01, *** p<0.001, 
Student’s t-test). Same scale bar used as d.
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